Maalox - antacid combination drug.
Release form and composition
Maalox is available in the following dosage forms:
- Chewable tablets: white, round, flat, with “Mx” engraving and chamfer (10 pieces in a blister, 1, 2, 4 blisters in a cardboard box);
- Chewable tablets (without sugar): yellowish to white with slight marbling, round, flat-cylindrical with a bevel, engraved with “MAALOX” on one side and “sans sucre” on the other, with the smell of lemon (10 pcs in a blister, 1, 2, 4 blisters in a carton box);
- Suspension for oral administration: almost white or white, reminiscent of milk, with the smell of mint (250 ml in dark glass bottles, 1 bottle in a carton box; 15 ml in bags (sachets), 30 pcs. In a carton box).
The composition of 1 chewable tablet and chewing sugar-free tablet contains active ingredients:
- Magnesium hydroxide - 400 mg;
- Algeldrat - 400 mg (in the form of hydrated alumina).
- Chewable tablets: starch with sucrose (sugar confectionery), sorbitol, mannitol, magnesium stearate, peppermint flavoring, saccharinate sodium, sucrose;
- Tablets Chewable (no sugar): sorbitol liquid (non-crystallizable), maltitol, magnesium stearate, lemon flavoring (flavor formulations, natural flavors, acacia (E414), citric acid (E330), butylated hydroxyanisole (E320), sodium saccharin, 85% glycerol, talc).
The composition of 1 ml suspension for oral administration includes active substances:
- Magnesium hydroxide - 40 mg;
- Algeldrat - 35 mg (in the form of aluminum hydroxide).
Auxiliary components: 10% hydrochloric acid citric acid monohydrate, mannitol, peppermint leaf oil, 70% sorbitol, methyl parahydroxybenzoate, propyl parahydroxybenzoate, sodium saccharinate, 30% hydrogen peroxide, purified water.
Indications for use
- Peptic ulcer and duodenal ulcer (during exacerbation);
- Acute gastroduodenitis, chronic gastroduodenitis with increased or normal secretory function (during exacerbation);
- Reflux esophagitis, hiatal hernia;
- Various dyspeptic symptoms, including heartburn, pain or discomfort in the area of epigastria, sour belching after errors in diet, excessive consumption of coffee, ethanol, nicotine, etc .;
- Dyspeptic symptoms due to the use of certain drugs (nonsteroidal anti-inflammatory drugs, glucocorticosteroids, etc.), including pain or discomfort in the area of epigastrium, heartburn, and sour belching (treatment and prevention).
- Severe renal failure;
- Fructose intolerance (due to the presence of sorbitol in the formulation);
- Age up to 15 years (for chewable tablets with or without sugar);
- Hypersensitivity to the drug.
Additional contraindications are:
- Chewable tablets: sucrase-isomaltase deficiency, glucose-galactose malabsorption syndrome;
- Chewable tablets (without sugar): maltitol intolerance.
Maalox should be taken with caution in patients with renal insufficiency and elderly patients, since the use of the drug in high doses may aggravate or cause bowel obstruction and intestinal obstruction. Also, in case of kidney failure, with prolonged use of the drug in high doses, plasma concentrations of aluminum and magnesium may increase, which may lead to the development of dementia, encephalopathy, microcytic anemia or aggravation of osteomalacia caused by dialysis.
Long-term therapy, the use of excessively high doses of Maalox, or the use of the drug in normal doses against the background of low dietary phosphate can lead to the development of phosphate deficiency, which is accompanied by hypercalciuria and increased bone resorption with the risk of osteomalacia. Therapy of patients with the risk of developing phosphate deficiency or prolonged use of the drug should be carried out under medical supervision.
Also, caution should be exercised when taking Maalox patients with porphyria who are on hemodialysis, pregnant women and those suffering from Alzheimer's disease.
The drug in the form of chewable tablets should be taken with caution in patients with diabetes.
Maalox in the form of a suspension for oral administration is prescribed with caution to lactating and pregnant women, as well as children under 12 years.
Dosing and Administration
Maalox is taken orally.
Chewable tablets (with or without sugar) should be absorbed or chewed thoroughly.
Adults and children from 15 years old are usually prescribed 3-4 times a day (1-2 hours after a meal and at night) 1-2 tablets or 15 ml (1 tablespoon) of suspension.
With reflux esophagitis, Maalox is taken shortly after a meal.
The maximum frequency of taking the drug - 6 times a day (up to 12 tablets per day). The duration of the therapeutic course is no more than 2-3 months. In the case of occasional intake of Maalox (for example, in case of discomfort after errors in the diet), 1-2 tablets are taken once a day.
Children scheme of use of the drug is determined by the attending physician.
As a rule, if the recommended dosing regimen is observed, the side effects are insignificant.
During therapy may develop the following disorders:
- Immune system: with unknown frequency - hypersensitivity reactions, including pruritus, urticaria, anaphylactic reactions and angioedema;
- Gastrointestinal tract: infrequently - constipation, diarrhea;
- Metabolism and nutrition: with an unknown frequency - hyperaluminemia, hypermagneemia, hypophosphatemia.
Patients with concomitant renal insufficiency may develop thirst, lower blood pressure and hyporeflexia.
It is necessary to observe a break of at least 2 hours between using Maalox with other drugs and at least 4 hours with fluoroquinolones.
In renal failure, prolonged use of the drug is not recommended.
Before using Maalox, lactating, pregnant women, and children should consult a doctor.
If the symptoms of the disease within 10 days of treatment persist or worsen, it is necessary to consult a doctor for a more accurate diagnosis and, possibly, correction of treatment.
Maalox permeable to X-rays.
With the simultaneous use of Maalox with quinidine, it is possible to increase the serum concentrations of quinidine and the development of its overdose.
Combined with Atenol, H 2 lincosamides, ketoconazole, iron salts, phenothiazine neuroleptics, rosuvastatin, penicillamine, levothyroxine, their absorption decreases (this interaction can be avoided by Observance of the intervals between the administration of these drugs and Maalox).
Care must be taken when applying Maalox with polystyrenesulfonate (kayeksalat).
When Maalox is combined with citrates, the plasma concentration of aluminum may increase, especially in patients with renal insufficiency.
Terms and conditions of storage
Keep out of reach of children at temperature up to 25 ° C.
- Chewable tablets (with sugar and without sugar) - 5 years;
- Suspension for oral administration - 3 years.